arrow
S

Shinya Rai

kindai university school of medicine
H指数:17
被引数:1,773

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis

真实世界中,sarilumab与Janus kinase抑制剂作为单药治疗类风湿关节炎的疗效比较

2026-01-020
OAAI
Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR)

POLASTAR研究:Pola-R-CHP在未经治疗的日本DLBCL患者中的多中心初步分析

2025-12-010
OA
Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells

抗精神病药物Chlorpromazine抑制STAT5信号通路,克服由门控突变FLT3-ITD/F691L介导的耐药性,并与Quizartinib在FLT3-ITD阳性细胞中协同作用

2025-09-300
OAAI
Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma

体细胞IRF4突变和胸腺趋向性在原发性纵隔大B细胞淋巴瘤中的作用

Blood
IF23.1
2025-06-240
OA
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma

一项CHOP联合抗CCR4抗体mogamulizumab治疗老年成人T细胞白血病/淋巴瘤患者的II期临床试验

Blood
IF23.1
2025-05-190
PRE
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma

CSF2RB基因突变导致经典霍奇金淋巴瘤中细胞因子依赖性的获得性功能表型。

BLOOD
IF23.1
2024-11-050
PRE
Long-term efficacy and safety of tucidinostat inpatients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results
2024-06-060
OAAI
Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type

骨髓/自然杀伤 (NK) 细胞前体急性白血病是一种独特的白血病类型

2023-12-152
OAAI
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

复发或难治性外周T细胞淋巴瘤患者口服HDAC抑制剂tucidinostat: IIb期结果

2022-10-0635
OAAI
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin在先前未经治疗的弥漫性大b细胞淋巴瘤中的应用

2022-01-27378
OA